Get the Stockscreener App
55.95
21.91%
-15.70
After Hours:
58.41
2.46
+4.40%
Disc Medicine Inc stock is traded at $55.95, with a volume of 4.91M.
It is down -21.91% in the last 24 hours and down -25.84% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$71.65
Open:
$71.63
24h Volume:
4.91M
Relative Volume:
7.79
Market Cap:
$2.11B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-15.25
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
-29.82%
1M Performance:
-25.84%
6M Performance:
-8.43%
1Y Performance:
+3.42%
1-Day Range:
$40.00
$73.97
1-Week Range:
$40.00
$79.80
52-Week Range:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
55.95 | 2.70B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA - MedCity News
Disc Medicine (IRON) Faces Setback After FDA Response - GuruFocus
TimesSquare Capital Management LLC Purchases Shares of 182,170 Disc Medicine, Inc. $IRON - MarketBeat
FDA issues complete response letter to Disc Medicine’s bitopertin NDA - Yahoo Finance
Disc Medicine stock slumps after FDA declines approval for inherited disorder drug over efficacy concerns - MSN
FDA slaps CRL on Disc Medicine’s bitopertin NDA - The Pharma Letter
(IRON) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
Disc Medicine (IRON) Drops 22% After FDA Response on Bitopertin - GuruFocus
Drug For Rare Genetic Disorder Goes From FDA Priority to Reject in Four Months - Bloomberg.com
Disc setback deepens questions about FDA’s accelerated approval commitment, value of new vouchers - BioCentury
Disc Medicine plunges on FDA Complete Response Letter for bitopertin (IRON:NASDAQ) - Seeking Alpha
Disc Medicine Receives FDA Complete Response on Bitopertin - TipRanks
Breaking: US FDA’s Bitopertin CRL Shows CNPV Cannot Overcome Surrogate Endpoint Woes - Citeline News & Insights
FDA Issues Complete Response Letter to Bitopertin For Erythropoietic Protoporphyria - HCPLive
Disc Medicine EPP Treatment Fails to Get FDA Accelerated Approval - marketscreener.com
Disc Medicine (NASDAQ:IRON) Trading Down 40%What's Next? - MarketBeat
Disc Medicine stock plunges after FDA issues Complete Response Letter - Investing.com
FDA issues complete response letter for Disc Medicine’s EPP drug By Investing.com - Investing.com Canada
Significant Drop for IronNet Stock (IRON) Amid Late-Day Trading - GuruFocus
FDA Responds to Bitopertin Application with Complete Response Letter - Intellectia AI
Disc Medicine Receives Complete Response Letter From FDA For Bitopertin For The Treatment Of EPP - TradingView
Disc Medicine plunges after FDA posts complete response letter for bitopertin - TipRanks
Disc Medicine confirms complete response letter from FDA for bitopertin - TipRanks
Disc Medicine (IRON) Addresses FDA Concerns with Confidence - GuruFocus
Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP - The Manila Times
US FDA declines to approve Disc Medicine's rare disease drug - Reuters
FDA Issues Complete Response Letter for Disc Medicine’s Bitopertin, Awaiting APOLLO Study Results for Potential Approval - Quiver Quantitative
FDA delays decision on rare disease drug, pushing verdict to 2027 - Stock Titan
Breakout Move: Is Disc Medicine Inc stock trending bullishWeekly Investment Recap & Community Driven Trade Alerts - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.- IRON - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-02-11 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Disc Medicine, Inc. (IRON) And Encourages Shareholders to Reach Out | NDAQ:IRON | Press Release - Stockhouse
Why retail investors favor Disc Medicine Inc. stockJuly 2025 Spike Watch & Safe Capital Preservation Plans - mfd.ru
2026-02-10 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Shareholders to Learn More About the Investigation | NDAQ:IRON | Press Release - Stockhouse
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc. (IRON) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
getLinesFromResByArray error: size == 0 - mfd.ru
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect - ACCESS Newswire
Hedge Fund Bets: Whats the beta of Disc Medicine Inc stockJuly 2025 Action & Entry Point Confirmation Alerts - baoquankhu1.vn
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Disc Medicine, Inc. (IRON) Investor Outlook: Unveiling a 51% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, ... - Bluefield Daily Telegraph
Trend Review: Will Disc Medicine Inc outperform during market rallies2025 Technical Overview & Daily Momentum Trading Reports - baoquankhu1.vn
Responsive Playbooks and the IRON Inflection - Stock Traders Daily
2026-02-01 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Stockholders to Connect | NDAQ:IRON | Press Release - Stockhouse
Atle Fund Management AB Purchases 21,038 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. (IRON) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Disc Medicine, Inc. (IRON) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
BMO Capital reaffirms Disc Medicine stock rating amid approval optimism By Investing.com - Investing.com Canada
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Disc Medicine Inc Stock (IRON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Khara Rahul | Chief Legal Officer |
Jan 20 '26 |
Sale |
69.74 |
1,000 |
69,740 |
37,793 |
| Khara Rahul | Chief Legal Officer |
Jan 02 '26 |
Option Exercise |
13.50 |
6,500 |
87,750 |
44,293 |
| Khara Rahul | Chief Legal Officer |
Jan 02 '26 |
Sale |
78.69 |
6,500 |
511,472 |
37,793 |
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):